Remimazolam Versus Dexmedetomidine for Sedation During Neuraxial
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18+
SponsorIcahn School of Medicine at Mount Sinai
About this trial
Patients presenting for a scheduled cesarean delivery who require a neuraxial anesthetic will be randomized to receive intravenous remimazolam or dexmedetomidine for procedural sedation during the placement of their spinal or epidural anesthesia.
Eligibility criteria
Qualifiers
Pregnant patient scheduled for cesarean delivery
≥ 18 years old
≥ 37 weeks gestational age
Disqualifiers
Pregnant patients < 18 years old
Pregnant patients < 37 weeks gestational age
Has known hypersensitivity to benzodiazepines or dexmedetomidine
Has history of chronic benzodiazepine use or misuse
Trial design
Treatments tested in this trial
- Remimazolam
- Dexmedetomidine
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov